{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T16:35:48Z","timestamp":1777480548134,"version":"3.51.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100014358","name":"Second Affiliated Hospital of Soochow University","doi-asserted-by":"publisher","award":["XKTJ-XK202406-3"],"award-info":[{"award-number":["XKTJ-XK202406-3"]}],"id":[{"id":"10.13039\/501100014358","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s40261-025-01511-1","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T14:46:46Z","timestamp":1766587606000},"page":"173-206","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Study on the Safety, Pharmacokinetics, and Pharmacodynamics of H018 Tablets, a Selective JAK1 Inhibitor, Upon Single- and Multiple-Dose Administration in Chinese Healthy Subjects"],"prefix":"10.1007","volume":"46","author":[{"given":"Juan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjia","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quanying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6679-5166","authenticated-orcid":false,"given":"Meng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,24]]},"reference":[{"key":"1511_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2018.1","volume":"4","author":"JS Smolen","year":"2018","unstructured":"Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4:18001.","journal-title":"Nat Rev Dis Primers"},{"issue":"7","key":"1511_CR2","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1136\/annrheumdis-2013-204627","volume":"73","author":"M Cross","year":"2014","unstructured":"Cross M, Smith E, Hoy D, Carmona L, Wolfe F, Vos T, et al. The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014;73(7):1316\u201322.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1511_CR3","first-page":"300","volume":"13","author":"XF Zeng","year":"2013","unstructured":"Zeng XF, Zhu SL, Tan AC, Xie XP. Disease burden and quality of life of rheumatoid arthritis in China: a systematic review. Chin J Evid Based Med. 2013;13(3):300\u20137.","journal-title":"Chin J Evid Based Med"},{"issue":"5","key":"1511_CR4","first-page":"836","volume":"36","author":"C Yu","year":"2018","unstructured":"Yu C, Li M, Duan X, Fang Y, Li Q, Wu R, et al. Chinese Registry of Rheumatoid Arthritis (CREDIT): I. Introduction and prevalence of remission in Chinese patients with rheumatoid arthritis. Clin Exp Rheumatol. 2018;36(5):836\u201340.","journal-title":"Clin Exp Rheumatol"},{"issue":"18","key":"1511_CR5","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1097\/CM9.0000000000002110","volume":"135","author":"N Jiang","year":"2022","unstructured":"Jiang N, Li Q, Li H, Fang Y, Wu L, Duan X, et al. Chinese registry of rheumatoid arthritis (CREDIT) V: sex impacts rheumatoid arthritis in Chinese patients. Chin Med J (Engl). 2022;135(18):2210\u20137.","journal-title":"Chin Med J (Engl)"},{"issue":"8","key":"1511_CR6","first-page":"526","volume":"17","author":"YS Zhou","year":"2013","unstructured":"Zhou YS, Wang XR, An Y, Li C, Zhang XY, Duan TJ, et al. A multicenter study of deformity and disability in rheumatoid arthritis patients in China. Chin J Rheumatol. 2013;17(8):526\u201332.","journal-title":"Chin J Rheumatol."},{"issue":"5","key":"1511_CR7","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s10067-015-2896-z","volume":"34","author":"SP Zhao","year":"2015","unstructured":"Zhao SP, Chen YL, Chen H. Sociodemographic factors associated with functional disability in outpatients with rheumatoid arthritis in Southwest China. Clin Rheumatol. 2015;34(5):845\u201351.","journal-title":"Clin Rheumatol"},{"issue":"27","key":"1511_CR8","first-page":"1873","volume":"89","author":"ZG Li","year":"2009","unstructured":"Li ZG. Facing the challenge of low recognition and high disability in rheumatoid arthritis. Natl Med J China. 2009;89(27):1873\u20135.","journal-title":"Natl Med J China"},{"issue":"4","key":"1511_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102776","volume":"20","author":"FA Figus","year":"2021","unstructured":"Figus FA, Piga M, Azzolin I, McConnell R, Iagnocco A. Rheumatoid arthritis: extra-articular manifestations and comorbidities. Autoimmun Rev. 2021;20(4):102776.","journal-title":"Autoimmun Rev"},{"issue":"3","key":"1511_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10030509","volume":"10","author":"PC Taylor","year":"2021","unstructured":"Taylor PC, Atzeni F, Balsa A, Gossec L, M\u00fcller-Ladner U, Pope J. The key comorbidities in patients with rheumatoid arthritis: a narrative review. J Clin Med. 2021;10(3):509.","journal-title":"J Clin Med"},{"issue":"1","key":"1511_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-017-1457-z","volume":"19","author":"S Jin","year":"2017","unstructured":"Jin S, Li M, Fang Y, Li Q, Liu J, Duan X, et al. Chinese Registry of Rheumatoid Arthritis (CREDIT): II. prevalence and risk factors of major comorbidities in Chinese patients with rheumatoid arthritis. Arthritis Res Ther. 2017;19(1):251.","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"1511_CR12","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1080\/13543784.2023.2199919","volume":"32","author":"S Kubo","year":"2023","unstructured":"Kubo S, Nakayamada S, Tanaka Y. JAK inhibitors for rheumatoid arthritis. Expert Opin Investig Drugs. 2023;32(4):333\u201344.","journal-title":"Expert Opin Investig Drugs"},{"key":"1511_CR13","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s40262-015-0240-z","volume":"54","author":"F Namour","year":"2015","unstructured":"Namour F, Diderichsen P, Cox E, Vayssi\u00e8re B, Van der Aa A, Tasset C, et al. Pharmacokinetics and pharmacokinetic\/pharmacodynamic modeling of filgotinib (GLPG0634), a selective JAK1 inhibitor, in support of phase IIB dose selection. Clin Pharmacokinet. 2015;54:859\u201374. https:\/\/doi.org\/10.1007\/s40262-015-0240-z.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"1511_CR14","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1002\/cpdd.659","volume":"8","author":"K Anderson","year":"2019","unstructured":"Anderson K, Zheng H, Kotecha M, Cuvin J, Scott B, Sharma S, et al. The relative bioavailability and effects of food and acid-reducing agents on filgotinib tablets in healthy subjects. Clin Pharmacol Drug Dev. 2019;8(5):585\u201394.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"1511_CR15","unstructured":"Gilead Sciences. Jyseleca summary of product characteristics. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/jyseleca-epar-product-information_en.pdf. Accessed 9 Oct 2021."},{"key":"1511_CR16","unstructured":"European Medicines Agency Committee for Medicinal Products for Human Use (CHMP). Assessment report: Jyseleca. EMA\/424374\/2020. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/jyseleca-epar-public-assessment-report_en.pdf. Accessed 4 Feb 2021."},{"key":"1511_CR17","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1111\/bcp.13726","volume":"84","author":"F Namour","year":"2018","unstructured":"Namour F, Fagard L, Van der Aa A, Harrison P, Xin Y, Tasset C. Influence of age and renal impairment on the steady state pharmacokinetics of flgotinib, a selective JAK1 inhibitor. Br J Clin Pharmacol. 2018;84:2779\u201389. https:\/\/doi.org\/10.1111\/bcp.13726.","journal-title":"Br J Clin Pharmacol"},{"key":"1511_CR18","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.3899\/jrheum.201183","volume":"48","author":"A Kavanaugh","year":"2021","unstructured":"Kavanaugh A, Westhovens RR, Winthrop KL, Lee SJ, Tan Y, An D, et al. Safety and efficacy of filgotinib: up to 4-year results from an open-label extension study of phase II rheumatoid arthritis programs. J Rheumatol. 2021;48:1230\u20138. https:\/\/doi.org\/10.3899\/jrheum.201183.","journal-title":"J Rheumatol"},{"key":"1511_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14397595.2021.1902617","volume":"32","author":"Y Tanaka","year":"2022","unstructured":"Tanaka Y, Kavanaugh A, Wicklund J, McInnes IB. Filgotinib, a novel JAK1-preferential inhibitor for the treatment of rheumatoid arthritis: an overview from clinical trials. Mod Rheumatol. 2022;32:1\u201311. https:\/\/doi.org\/10.1080\/14397595.2021.1902617.","journal-title":"Mod Rheumatol"},{"issue":"6","key":"1511_CR20","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s40262-022-01129-y","volume":"61","author":"F Namour","year":"2022","unstructured":"Namour F, Anderson K, Nelson C, Tasset C. Filgotinib: a\u00a0clinical pharmacology review. Clin Pharmacokinet. 2022;61(6):819\u201332.","journal-title":"Clin Pharmacokinet"},{"key":"1511_CR21","unstructured":"European Medicines Agency. Filgotinib (Jyseleca\u00ae): summary of product characteristics. 2020. Available from: https:\/\/www.ema.europa.eu\/https:\/\/www.ema.europa.eu\/. Accessed."},{"key":"1511_CR22","doi-asserted-by":"publisher","first-page":"3568","DOI":"10.4049\/jimmunol.1201348","volume":"191","author":"L Van Rompaey","year":"2013","unstructured":"Van Rompaey L, Galien R, van der Aar EM, Clement-Lacroix P, Nelles L, Smets B, et al. Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases. J Immunol. 2013;191:3568\u201377. https:\/\/doi.org\/10.4049\/jimmunol.1201348.","journal-title":"J Immunol"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01511-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-025-01511-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01511-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T04:35:23Z","timestamp":1770179723000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-025-01511-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,24]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1511"],"URL":"https:\/\/doi.org\/10.1007\/s40261-025-01511-1","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,24]]},"assertion":[{"value":"4 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mei Su is an employee of Jiangsu Carephar Pharmaceutical Co., Ltd., Nanjing City, Jiangsu Province, P.R. China at the time of this research. Juan Zhang, Wenjia Zhou, Quanying Zhang, and Meng Wang have no conflicts of interest that are directly relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study protocol was reviewed and approved by the Independent Ethics Committee of the Second Affiliated Hospital of Soochow University (approval numbers: JD-LS-2021-138-1, JD-LS-2022-156-A01 and JD-LS-2022-156-A02).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Prior to study entry, all subjects reviewed and signed an informed consent document explaining the study procedures and potential risks.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets generated and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"QZ, MS, and MW were responsible for the study concept and study design. JZ, WZ, QZ, and MW were responsible for study conduct and data acquisition. WZ, QZ, MS, and MW were responsible for analysis and interpretation. WZ was responsible for original draft preparation. WZ and MW were responsible for draft review and editing. All authors have read and agreed to the final version of this manuscript. All authors also confirm accountability for the accuracy and integrity of the work.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}